NCT04264936Unknown1 期
A Open-label, Single-arm, Phase Ib/II Study of RC48-ADC and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer
Peking University Cancer Hospital & Institute1 个研究点 分布在 1 个国家目标入组 36 人开始时间: 2020年2月15日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 36
- 试验地点
- 1
- 主要终点
- Adverse events
研究概览
简要总结
This is an open-label, single-arm, Phase Ib/II investigator-initiated trial of RC48-ADC combined with JS001 to evaluate the safety and pharmacokinetics of subjects with locally advanced or metastatic urothelial cancer
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent form; Aged 18 years and above; ECOG(Eastern Cooperative Oncology Group) performance is 0 or 1; Life expectancy greater than 12 weeks; Patients with locally advanced or metastatic malignant urothelial carcinoma which is platinum naive and cisplatin ineligible, or progressed after at least one line standard systemic chemotherapy (including progression within 12 months of neo-/adjuvant therapy);
- •Cisplatinum ineligible patients should meet one of the following criteria:
- •Aged 70 years and above, and ECOG performance is 1;
- •Serum creatinine >= 1.0xULN or CrCl<60ml/min;
- •Lose of hearing >= Grade 2;
- •Peripheral nerve disorder >= Grade 2 Patients with measurable and appreciable tumor lesions according to Response Evaluation Criteria in Solid Tumors (RECIST 1.1); Willing to provide primary lesion samples for the purpose of PD-L1 and HER2 tests.
- •Adequate organ function as defined by the following criteria:
- •absolute neutrophil count(ANC) >= 1.5 x 10^9/L;
- •platelets>=100* 10^9/L;
- •Total serum creatinine <=1.5*ULN;
- •serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=2.5*upper limit of normal (ULN), or AST and ALT<=5*ULN if liver function abnormalities are due to underlying malignancy; normal serum creatinine ;
- •Left ventricular ejection fraction (LVEF) >=50%
- •Hemoglobin>=9g/dl Women of child-bearing potential and men must agree to use adequate contraception (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete sexual abstinence, or sterilized partner) prior to study entry and during the period of therapy and for 30 days after the last dose of study drug;
排除标准
- •Allergy to RC48-ADC, or JS001, or their components Received anti-cancer therapy including chemotherapy, radiotherapy, immunotherapy or other clinical trial treatments within 3 weeks of starting study treatment Unresolved toxicities from prior anti-cancer therapy, except for alopecia Previously treated with HER2-ADC and/or anti-PD-1 or anti-PD-L1 or anti PD-L2 therapies; Underwent major surgery within 4 weeks of first dose of study drug and not completely recovered; Received vaccine within 4 weeks of first dose of study drug Currently active clinically significant cardiovascular disease such as uncontrolled arrhythmia, congestive heart failure, or greater than or equal to Class 2 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction unstable angina, or acute coronary syndrome within 6 months prior to enrollment in the study; History of other neoplastic disease within 3 years prior to the study drug, with exception of resolved/curable cancers such as basal skin cancer or squamous cell skin cancer,.
- •Metastasis to CNS(central nervous system) and/or carcinomatous meningitis, with exception for the patients who received treatment of metastasis to CNS and/or carcinomatous meningitis and had stable disease for at least 3 months, and no evidence of progression within 4 weeks of first dose of study treatment. No evidence of new or expanded metastasis, and untreated with radiotherapy, surgery or steroid therapy within 4 weeks of first dose of study treatment.
- •History of allogeneic hematopoietic stem cell transplantation or organ transplantation; Patients who had received systemic steroid therapy within the last 2 years; Pregnancy or lactation; Positive results of HIV testing; Active HBV(hepatitis B virus) or HCV(hepatitis C virus) infection Active tuberculosis; Other disorders with clinical significance according to the researcher's judgment; Unwilling or unable to participate in all required study evaluations and procedures
研究组 & 干预措施
RC48-ADC and JS001
Experimental
干预措施: RC48-ADC and JS001 (Drug)
结局指标
主要结局
Adverse events
时间窗: through study completion, an average of 1 year
rate of adverse events
maximal tolerated dose
时间窗: through study completion, an average of 1 year
dose-limiting toxity
次要结局
- Peak Plasma Concentration(Cmax)(through study completion, an average of 1 year)
- Immunogenicity(through study completion, an average of 1 year)
- objective response rate(From date of randomization until the date of first documented progression or date of death from any cause, whichever came first；assessed up to 60 months)
- the area under the curve (AUC)(through study completion, an average of 1 year)
研究者
Jun Guo
Director
Peking University Cancer Hospital & Institute
研究点 (1)
Loading locations...
相似试验
尚未招募
2 期
An Open-label, Single-arm, Multicenter Phase II Clinical Study： Evaluating RC48-ADC Combined With Triplizumab in the Neoadjuvant Treatment of Her2-positive Muscle-invasive Bladder CancerNeoadjuvant Treatment of Her2-positive Muscle-invasive Bladder CanceNCT05356351Tianjin Medical University Cancer Institute and Hospital30
尚未招募
1 期
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 MutationNon-small Cell Lung CancerNCT05745740RemeGen Co., Ltd.26
Unknown
2 期
A Study of RC48-ADC for the Treatment of HER2-expression Metastatic Breast Cancer With Abnormal Activation of PAM PathwayMetastatic Breast CancerNCT05331326Cancer Institute and Hospital, Chinese Academy of Medical Sciences64
尚未招募
2 期
Clinical Study on the Efficacy and Safety of RC48-ADC in the Treatment of Metastatic Castration Resistant Prostate Cancer (mCRPC)Metastatic Castration-resistant Prostate CancerNCT05955209Peking University Cancer Hospital & Institute40
招募中
2 期
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological MalignanciesGynecological MalignancyNCT04965519RemeGen Co., Ltd.120